Siegfried secures US$595.8M syndicated facility to refinance bridge loan
What's the deal? Swiss pharmaceutical manufacturer Siegfried Holding AG has secured a new syndicated US$595.8M term and revolving credit facilities agreement, with UBS Switzerland AG acting as mandated lead arranger, coordinator, and agent.
What's it for? The proceeds will refinance an existing bridge facility and fund general corporate purposes.
Who's involved? UBS led the entire banking syndicate. Law firm Walder WyssDealroom has a profile for this one. Try Dealroom → advised UBS and the syndicate, fielding a team led by partners Lukas Wyss and Maurus Winzap, alongside associate Valentin Freiermuth.
What's the endgame? Siegfried is a global Contract Development and Manufacturing Organization (CDMO) for the pharmaceutical industry. Replacing short-term bridge debt with longer-dated facilities gives it a more stable funding base to support operations.
The signal: The size and structure of the deal — a syndicated facility rather than a single lender — reflect continued bank appetite for financing established players in pharmaceutical manufacturing, a sector underpinned by steady demand for outsourced drug production.
Read more: Walder Wyss
Image credit: Generated with Gemini
